Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $41.70 USD
Change Today -0.38 / -0.90%
Volume 249.7K
HAE On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

haemonetics corp/mass (HAE) Snapshot

Open
$42.00
Previous Close
$42.08
Day High
$42.37
Day Low
$41.57
52 Week High
02/27/15 - $45.43
52 Week Low
06/2/14 - $33.20
Market Cap
2.1B
Average Volume 10 Days
221.4K
EPS TTM
$1.16
Shares Outstanding
51.5M
EX-Date
--
P/E TM
36.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for HAEMONETICS CORP/MASS (HAE)

Related News

No related news articles were found.

haemonetics corp/mass (HAE) Related Businessweek News

No Related Businessweek News Found

haemonetics corp/mass (HAE) Details

Haemonetics Corporation is engaged in the design, development, manufacture, and marketing of automated blood component collection devices and surgical blood salvage devices in the United States and internationally. It provides various plasma products, including PCS brand plasma collection equipment and consumables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and blood center products comprising multicomponent collection system brand apheresis equipment to collect specific blood components integrated from the donor, automated cell processor brand solution to automate the washing and freezing of red cell components in the lab, and filtration products. The company also offers various hospital products, such as TEG thrombelastograph hemostasis analyzer system that measures a patient's hemostasis or the ability to form and maintain blood clots; Cell Saver system for cardiovascular surgery procedures; OrthoPAT surgical blood salvage system for orthopedic procedures; and IMPACT Online Web-based software platform that monitors and measures improvements in a hospital’s blood management practices. In addition, it offers SafeTrace Tx and BloodTrack suite of solutions, as well as El Dorado Donor donation and blood unit management systems. The company markets and sells its products to bio-pharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations, and national health organizations through its direct sales force, as well as independent distributors. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

haemonetics corp/mass (HAE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $718.0K
President of Global Plasma
Total Annual Compensation: $588.9K
Executive Vice President of Global Manufactur...
Total Annual Compensation: $455.0K
Chief Science & Technology Officer
Total Annual Compensation: $441.0K
Compensation as of Fiscal Year 2014.

haemonetics corp/mass (HAE) Key Developments

Haemonetics Corporation Announces Board Changes

Haemonetics Corporation announced expanded roles for two executives. These changes are part of an ongoing plan to advance the company's global leadership in blood management solutions and to execute on strategies to enhance shareholder value. Kent Davies, who joined the company in 2014, is appointed to the new position of Chief Operating Officer, reporting directly to Brian Concannon, President and CEO. In this expanded role, Mr. Davies will have overall accountability for the company's commercial, product development and product management focus across the entire portfolio and in all geographies. Byron Selman, who joined the company upon the acquisition of Pall Corporation's transfusion medicine business in 2012, is appointed to the position of President, Global Markets, reporting to Mr. Davies. Mr. Selman will oversee the Company's global commercial and market development efforts, with the exception of the company's commercial Plasma business.

Berendsen plc Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Fiscal Year Ended March 28, 2015; Provides Earnings Guidance for the Fiscal 2016

Berendsen plc reported unaudited consolidated earnings results for the fourth quarter and full year ended March 28, 2015. For the quarter, the company reported net revenues of $226,478,000 compared to $241,091,000 a year ago. Operating income was of $11,538,000 compared to $12,367,000 a year ago. Income before taxes was of $9,659,000 compared to $9,755,000 a year ago. Net loss was $2,930,000 compared to net profit of $10,184,000 a year ago. Net loss per common share assuming dilution was $0.06 compared to net income per common share assuming dilution of $0.19 a year ago. GAAP cash flow from operations was $55,599,000 compared to $51,471,000 a year ago. Capital expenditures were $21,942,000 compared to $29,927,000 a year ago. Non-GAAP operating income was $35,191,000 compared to $34,236,000 a year ago. Non-GAAP income before taxes was $32,606,000 compared to $31,624,000 a year ago. Non-GAAP net income was $24,453,000 or $0.47 per diluted share compared to $24,193,000 or $0.46 per diluted share a year ago. For the year, the company reported net revenues of $910,373,000 compared to $938,509,000 a year ago. Operating income was of $40,540,000 compared to $46,432,000 a year ago. Income before taxes was of $31,165,000 compared to $36,401,000 a year ago. Net income was $16,897,000 compared to $35,148,000 a year ago. Net income per common share assuming dilution was $0.32 compared to $0.67 a year ago. GAAP cash flow from operations was $127,430,000 compared to $139,524,000 a year ago. Capital expenditures were $122,472,000 compared to $73,648,000 a year ago. Non-GAAP operating income was $137,503,000 compared to $159,239,000 a year ago. Non-GAAP income before taxes was $128,128,000 compared to $149,208,000 a year ago. Non-GAAP net income was $96,222,000 or $1.85 per diluted share compared to $114,443,000 or $2.19 per diluted share a year ago. Overall fiscal 2016 revenue is expected to grow 4% to 6% on a reported basis and 7% to 9% in constant currency. The Company expects strong revenue growth from its identified growth drivers of Plasma, TEG and Emerging Markets, double digit increase in Software, an emerging growth driver, and the benefit of a 53 week in fiscal 2016, partially offset by a moderating revenue headwind in the U.S. blood center business and currency weakness. Income taxes are expected to approximate 24% of pre-tax adjusted income. Adjusted earnings per share, excluding remaining VCC transformation expenses and deal amortization, are expected in the range of $1.98 to $2.08, an increase of 7% to 2% over fiscal 15. In constant currency, fiscal 2016 earnings growth is expected to be in the range of 15% to 20%. Fiscal 2016 free cash flow is expected to approximate $105 million to $110 million before funding restructuring and capital investment for transformation activities. The Company anticipates investing $27 million of free cash flow to fund the remaining capital expenditures and cash transformation expenditures to complete the VCC initiatives in fiscal 2016.

Haemonetics Corporation to Report Q4, 2015 Results on Apr 27, 2015

Haemonetics Corporation announced that they will report Q4, 2015 results at 8:00 AM, Eastern Daylight on Apr 27, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HAE:US $41.70 USD -0.38

HAE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cerner Corp $67.83 USD -0.36
Fresenius SE & Co KGaA €57.33 EUR -0.257
McKesson Corp $239.44 USD -2.36
Medtronic PLC $78.41 USD -0.38
Terumo Corp ¥2,825 JPY -26.00
View Industry Companies
 

Industry Analysis

HAE

Industry Average

Valuation HAE Industry Range
Price/Earnings 100.0x
Price/Sales 2.4x
Price/Book 2.6x
Price/Cash Flow 128.2x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HAEMONETICS CORP/MASS, please visit www.haemonetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.